Management tracks: Century Therapeutics, Passage, Forbion, Bavarian, Disc, Biocartis, QuantuMDx and more

Century Therapeutics LLC appointed Joseph Jimenez, former CEO of Novartis AG (NYSE:NVS; SIX:NOVN), to its board. Jimenez retired in 2018 after eight years at the pharma’s helm, leading it through multiple patent expirations, business integrations and reorganizations (see “CMO Narasimhan to Replace CEO Jimenez”).

Century, which is

Read the full 464 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers